Insights

We are focused on understanding how inflammation and fibrosis contribute to diseases of the heart and developing therapies, now in clinical trials for rare cardiac conditions, to target these mechanisms and promote healing.

Blog

No items found.

Community Engagement

Myocarditis Foundation logo

Myocarditis Foundation

The Myocarditis Foundation is a voluntary, non-profit organization that is dedicated to providing information about myocarditis to medical professionals, patients and their families, with the goal of saving more lives.

Learn More
Pericarditis Alliance logo

Pericarditis Alliance

The Pericarditis Alliance is a nonprofit organization dedicated to the diagnosis, management, and treatment of pericardial disease through research, education, and support for patients and healthcare providers.

Learn More

Resources

Cannabidiol: Mechanisms and Effects

Cannabidiol has been shown to demonstrate anti-inflammatory and anti-fibrotic effects, including attenuating multiple inflammatory signaling pathways known to play an important role in pericarditis, myocarditis, and heart failure. An overview of cannabidiol’s effects on these cellular targets are described below.

18/01/2024

An Overview of Cannabidiol as a Multifunctional Drug: Pharmacokinetics and Cellular Effects

by Martinez Naya N, Kelly J, Corna G, et al.. Molecules. 2024;29(2):473.
View Online
15/11/2023

Cannabidiol inhibits the mesothelial to mesenchymal transition in experimental pericarditis

by Martinez Naya N et al. 2023 Annual Meeting of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases: Poster Viewing Sessions
View Online
7/10/2023

Cannabidiol As A Potential Treatment For Heart Failure With Preserved Ejection Fraction

by Lozano O et al. Heart Failure Society of America Annual Scientific Meeting 2023: ePoster Viewing Session III.
View Online
8/09/2023

Molecular and Cellular Mechanisms of Action of Cannabidiol

by Martinez Naya N, Kelly J, Corna G, et al. Molecules. 2023;28(16):5980.
View Online
23/02/2023

Cannabidiol Inhibits Endothelial-to-mesenchymal Transition and also Promotes the Reverse Process in vitro

by Krishnamoorthi MK, Youker KA, Bhimaraj A. Annual Scientific Meeting of the Heart Failure Society of America 2022: Basic and Translational Science Posters.
View Online
23/02/2023

Cardioprotective Effect of Cannabidiol in a Non-Ischemic Model of Heart Failure

by Lozano O, García-Rivas G, Ramos M, et al. J Am Coll Cardiol. 2020 Mar, 75 (11_Supplement_1) 705.
View Online
5/11/2022

Protective Effects of Pharmaceutically Manufactured Cannabidiol in a Mouse Model of Acute Pericarditis

by Martinez-Naya N, Nirar AH, Kim MM et al. American Heart Association Scientific Sessions 2022: Late-Breaking Basic Science Posters (LBP24).
View Online
18/08/2020

Cannabidiol as a Novel Therapeutic for Immune Modulation

by Peyravian N, Deo S, Daunert S, Jimenez JJ. Immunotargets Ther. 2020;9:131-140.
View Online
8/01/2016

Cannabidiol Limits T Cell-Mediated Chronic Autoimmune Myocarditis: Implications to Autoimmune Disorders and Organ Transplantation

by Lee WS, Erdelyi K, Matyas C, et al. Mol Med. 2016;22:136-146.
View Online
1/06/2012

Is the Cardiovascular System a Therapeutic Target for Cannabidiol?

by Stanley CP, Hind WH, O'Sullivan SE. Br J Clin Pharmacol. 2013;75(2):313-322.
View Online
14/12/2010

Cannabidiol attenuates Cardiac Dysfunction, Oxidative Stress, Fibrosis, and Inflammatory and Cell Death Signaling Pathways in Diabetic Cardiomyopathy

by Rajesh M, Mukhopadhyay P, Bátkai S, et al. J Am Coll Cardiol. 2010;56(25):2115-2125.
View Online

Inflammation, the Inflammasome, and Fibrosis in Cardiovascular Diseases

Aberrant activation of inflammatory pathways plays a role in many cardiovascular diseases which lead to the inflammation and fibrotic responses that are associated with contributing to the pathogenesis and progression of heart diseases.  The papers below provide a summary of how these pathways and mechanisms contribute to pericarditis, myocarditis, and heart failure, and offer insight into their potential as therapeutic targets.

7/04/2022

Emerging Roles of Inflammasomes in Cardiovascular Diseases

by Liao Y, Liu K, Zhu L. Emerging Roles of Inflammasomes in Cardiovascular Diseases. Front Immunol. 2022;13:834289.
View Online
1/04/2022

The Inflammasome as a Therapeutic Target for Myopericardial Diseases

by Imazio M, Abbate A. Minerva Cardiol Angiol. 2022;70(2):238-247.
View Online
3/11/2021

Targeting the Inflammasome in Cardiovascular Disease

by Olsen MB, Gregersen I, Sandanger Ø, et al. JACC Basic Transl Sci. 2021;7(1):84-98.
View Online
11/10/2021

Inflammation in Human Heart Failure: Major Mediators and Therapeutic Targets

by Reina-Couto M, Pereira-Terra P, Quelhas-Santos J, et al. Front Physiol. 2021;12:746494.
View Online
22/02/2021

The Role of NLRP3 Inflammasome in Pericarditis: Potential for Therapeutic Approaches

by Mauro AG, Bonaventura A, Vecchié A, et al. JACC Basic Transl Sci. 2021;6(2):137-150.
View Online
24/03/2020

Inflammation in Heart Failure: JACC State-of-the-Art Review

by Murphy SP, Kakkar R, McCarthy CP, Januzzi JL Jr. J Am Coll Cardiol. 2020;75(11):1324-1340.
View Online

Heart Disease, Pericarditis, Myocarditis and Heart Failure

Conditions affecting the heart are often life-threatening and debilitating. The publications below provide an overview of the impact of pericarditis, myocarditis, and heart failure on patients and healthcare, and include clinical guidelines which describe the causes, symptoms, diagnosis, and management of these diseases.

24/01/2024

2024 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association

by Seth S. Martin, Aaron W. Aday, Zaid I. Almarzooq, et al. Circulation. 2024;149:e347–e913
View Online
20/10/2022

Myocarditis

by Basso C. Myocarditis. N Engl J Med. 2022;387(16):1488-1500.
View Online
3/05/2022

2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines

by Heidenreich PA, Bozkurt B, Aguilar D, et al. Circulation. 2022;145(18):e895-e1032.
View Online
29/12/2021

Burden of Heart Failure and Underlying Causes in 195 Countries and Territories from 1990 to 2017

by Bragazzi NL, Zhong W, Shu J, et al. Eur J Prev Cardiol. 2021;28(15):1682-1690.
View Online
21/09/2021

2021 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure

by McDonagh TA, Metra M, Adamo M, et al. Eur Heart J. 2021;42(36):3599-3726.
View Online
18/03/2021

Myocarditis and Inflammatory Cardiomyopathy: Current Evidence and Future Directions

by Tschöpe C, Ammirati E, Bozkurt B, et al. Nat Rev Cardiol. 2021;18(3):169-193.
View Online
7/01/2020

Management of Acute and Recurrent Pericarditis: JACC State-of-the-Art Review

by Chiabrando JG, Bonaventura A, Vecchié A, et al. J Am Coll Cardiol. 2020;75(1):76-92.
View Online
29/08/2015

2015 ESC Guidelines for the Diagnosis and Management of Pericardial Diseases

by Adler Y, Charron P, Imazio M, et al. Eur Heart J. 2015;36(42):2921-2964.
View Online